Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma

BackgroundHuman Disabled-2 (DAB2), is a multi-function signalling molecule that it is frequently down-regulated in human cancers. We aimed to investigate the possible tumour suppressor effect of DAB2 in nasopharyngeal carcinoma (NPC).MethodsWe studied the expression of DAB2 in NPC cell lines, xenografts and primary tumour samples. The status of promoter methylation was assessed by methylation specific PCR and bisulfite sequencing. The functional role of DAB2 in NPC was investigated by re-introducing DAB2 expression into NPC cell line C666-1.ResultsDecrease or absent of DAB2 transcript was observed in NPC cell lines and xenografts. Loss of DAB2 protein expression was seen in 72% (33/46) of primary NPC as demonstrated by immunohistochemistry. Aberrant DAB2 promoter methylation was detected in 65.2% (30/46) of primary NPC samples by methylation specific PCR. Treatment of the DAB2 negative NPC cell line C666-1 with 5-aza-2'-deoxycytidine resulted in restoration of DAB2 expression in a dose-dependent manner. Overexpression of DAB2 in NPC cell line C666-1 resulted in reduced growth rate and 35% reduction in anchorage-dependent colony formation, and inhibition of serum-induced c-Fos expression compared to vector-transfected controls. Over expression of DAB2 resulted in alterations of multiple pathways as demonstrated by expression profiling and functional network analysis, which confirmed the role of DAB2 as an adaptor molecule involved in multiple receptor-mediated signalling pathways.ConclusionsWe report the frequent down regulation of DAB2 in NPC and the promoter hypermethylation contributes to the loss of expression of DAB2. This is the first study demonstrating frequent DAB2 promoter hypermethylation in human cancer. Our functional studies support the putative tumour suppressor effect of DAB2 in NPC cells.

[1]  K. To,et al.  High resolution allelotype of microdissected primary nasopharyngeal carcinoma. , 2000, Cancer research.

[2]  J. Kwong,et al.  Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma , 2005, International journal of cancer.

[3]  R. Erikson,et al.  The polo-box-dependent induction of ectopic septal structures by a mammalian polo kinase, plk, in Saccharomyces cerevisiae. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Baldini,et al.  DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer , 1998, Oncogene.

[5]  C. Tseng,et al.  Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells. , 1998, Endocrinology.

[6]  Kwok Wai Lo,et al.  Focus on nasopharyngeal carcinoma. , 2004, Cancer cell.

[7]  Jonathan A. Cooper,et al.  Disabled‐2 Colocalizes with the LDLR in Clathrin‐Coated Pits and Interacts with AP‐2 , 2001, Traffic.

[8]  Xiang-Xi Xu,et al.  Cell cycle-dependent phosphorylation of Disabled-2 by cdc2 , 2003, Oncogene.

[9]  Elizabeth R. Smith,et al.  Disabled-2 Exerts Its Tumor Suppressor Activity by Uncoupling c-Fos Expression and MAP Kinase Activation* , 2001, The Journal of Biological Chemistry.

[10]  H. Friess,et al.  Down-Regulation of DOC-2 in Colorectal Cancer Points to Its Role as a Tumor Suppressor in This Malignancy , 2002, Diseases of the colon and rectum.

[11]  Yair Lotan,et al.  Decreased DOC-2/DAB2 Expression in Urothelial Carcinoma of the Bladder , 2007, Clinical Cancer Research.

[12]  J. Kwong,et al.  High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. , 2001, Cancer research.

[13]  J. Kwong,et al.  RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma , 2004, International journal of cancer.

[14]  C. Tseng,et al.  Synergistic induction of DOC-2/DAB2 gene expression in transitional cell carcinoma in the presence of GATA6 and histone deacetylase inhibitor. , 2005, Cancer research.

[15]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[16]  A. Hui,et al.  Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation , 1999, International journal of cancer.

[17]  Y. Jiang,et al.  The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin , 2008, Oncogene.

[18]  C. Tseng,et al.  The role of DOC-2/DAB2 in modulating androgen receptor-mediated cell growth via the nongenomic c-Src-mediated pathway in normal prostatic epithelium and cancer. , 2005, Cancer research.

[19]  C. Tseng,et al.  The Mechanism of Growth-inhibitory Effect of DOC-2/DAB2 in Prostate Cancer , 2002, The Journal of Biological Chemistry.

[20]  Jonathan A. Cooper,et al.  Myosin VI Binds to and Localises with Dab2, Potentially Linking Receptor‐Mediated Endocytosis and the Actin Cytoskeleton , 2002, Traffic.

[21]  Yusuke Nakamura,et al.  Epigenetic inactivation of the deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma , 2007, Genes, chromosomes & cancer.

[22]  J. Hsieh,et al.  The Inhibitory Role of DOC-2/DAB2 in Growth Factor Receptor-mediated Signal Cascade , 2001, The Journal of Biological Chemistry.

[23]  J. Hsieh,et al.  Characterization of a Novel Negative Regulator (DOC-2/DAB2) of c-Src in Normal Prostatic Epithelium and Cancer* , 2003, The Journal of Biological Chemistry.

[24]  Elizabeth R. Smith,et al.  c‐fos elimination compensates for disabled‐2 requirement in mouse extraembryonic endoderm development , 2009, Developmental dynamics : an official publication of the American Association of Anatomists.

[25]  F. Dong,et al.  Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2). , 2000, Genomics.

[26]  M. Fukayama,et al.  Epstein–Barr virus and gastric carcinoma: virus–host interactions leading to carcinoma , 2008, Cancer science.

[27]  Siddhartha Datta Gupta,et al.  Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis. , 2006, World journal of gastroenterology.

[28]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[29]  R. Berkowitz,et al.  DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases , 1998, Oncogene.

[30]  J. Herman,et al.  GATA-4 and GATA-5 Transcription Factor Genes and Potential Downstream Antitumor Target Genes Are Epigenetically Silenced in Colorectal and Gastric Cancer , 2003, Molecular and Cellular Biology.

[31]  Xiang-Xi Xu,et al.  Disabled-2 inactivation is an early step in ovarian tumorigenicity , 1999, Oncogene.

[32]  P. Howe,et al.  Disabled-2 (Dab2) Mediates Transforming Growth Factor β (TGFβ)-stimulated Fibronectin Synthesis through TGFβ-activated Kinase 1 and Activation of the JNK Pathway* , 2005, Journal of Biological Chemistry.

[33]  Qian Tao,et al.  Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. , 2009, Gastroenterology.

[34]  C. Rock,et al.  Cloning of a Novel Phosphoprotein Regulated by Colony-stimulating Factor 1 Shares a Domain with the Drosophiladisabled Gene Product (*) , 1995, The Journal of Biological Chemistry.

[35]  Louis V. DePaolo,et al.  Pre-Application Technical Assistance Webinar for NICHD Program Announcements for Vulvodynia - Systematic Epidemiologic, Etiologic, or Therapeutic Studies (NOT-HD-11-015) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institutes of Health (NIH) , 2011 .

[36]  L. You,et al.  Nasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis , 2008, Head & neck.

[37]  R. Ralhan,et al.  Frequent loss of Dab2 protein and infrequent promoter hypermethylation in breast cancer , 2007, Breast Cancer Research and Treatment.

[38]  A. Hui,et al.  Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. , 2003, Cancer genetics and cytogenetics.

[39]  Ying Liang,et al.  Activation of DNA methyltransferase 1 by EBV LMP1 Involves c-Jun NH(2)-terminal kinase signaling. , 2006, Cancer research.

[40]  P. Howe,et al.  Disabled-2 (Dab2) Is Required for Transforming Growth Factor β-induced Epithelial to Mesenchymal Transition (EMT)* , 2005, Journal of Biological Chemistry.

[41]  Jonathan A. Cooper,et al.  Regulation of the Wnt signaling pathway by disabled‐2 (Dab2) , 2003, The EMBO journal.

[42]  J. Kwong,et al.  Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  A. Hui,et al.  Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma , 2003, Molecular carcinogenesis.

[44]  S. Tsao,et al.  Establishment of two immortalized nasopharyngeal epithelial cell lines using SV40 large T and HPV16E6/E7 viral oncogenes. , 2002, Biochimica et biophysica acta.

[45]  Xiang-Xi Xu,et al.  Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2 , 1998, Oncogene.

[46]  Xiang Xu,et al.  Erratum: Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product (Journal of Biological Chemistry (1995) 270 (14184-14191)) , 1996 .